Send me real-time posts from this site at my email

Stephens analysts rate Guardant Health (NASDAQ:GH) as Overweight.

Originally published on Best Stocks
Category: best stocks to buy now

According to a research note titled “The Fly” that was reportedly distributed to clients and investors on Wednesday by stock researchers at Stephens, who had assumed coverage on shares of Guardant Health, “The Fly” was recently in the news for several reasons (NASDAQ: GH). First, the stock received an “overweight” rating from the financial services company.

Deposit $100 and get a $110 to trade stocks
>>>>>>>>>>Open Account

Not too long ago, several other research analysts also published the results of their investigations into the company in the form of research studies. In a study report published on August 1 and given by OTR Global, Guardant Health was given a rating of “good” by OTR Global. The “buy” recommendation that Goldman Sachs Group had previously held for Guardant Health was removed, and the price objective they had previously held for the company was reduced from $90.00 to $80.00. A research report published on August 8 made both of these alterations available to the general public for the first time. In a research report released on August 8, Morgan Stanley lowered the “overweight” rating they had previously assigned to Guardant Health.
Additionally, they lowered their price objective for the stock from $85.00 to $80.00, which they had previously set at $85.00. The Credit Suisse Group published a research note on August 24 announcing it would begin covering Guardant Health. The note was issued on Wednesday. They assigned the company an “outperform” rating and projected that the stock would reach $800.00 within the next three months. The stock comes with a “buy” recommendation from fourteen analysts across the industry. The information discovered on revealed that the company has been given the rating of “Buy” at present and is expected to achieve an average price of $115.75 in the not-too-distant future.
The price of one share of Guardant Health increased by $0.16 during the trading session at noon on Wednesday, which ultimately reached $59.78. The number of shares the company traded was 1,104,140, which is significantly less than the typical volume of 1,184,059 shares the company. The share currently trades at a price that results in a price-to-earnings ratio of -11.05 and a beta value of 0.71. The stock has a market value of $6.11 billion. Over the previous twelve months, the cost of Guardant Health ranged from a minimum of $27.65 to a maximum of $121.26. There is a ratio of 3.56 debt to equity, a 5.83 quick ratio to current ratio, and a 6.18 current ratio to quick ratio. The ratio of the current ratio to the quick ratio is the highest. The company’s moving averages over the previous fifty and two hundred days are $52.96 and $51.32, respectively.

On August 4, the most recent quarterly results report for Guardant Health, found on the NASDAQ under the symbol GH, was made public. The company’s actual earnings per share for the quarter came in at $2.25, which is $1.00 less than the average estimate of $1.25, which indicates that the company did better than expected. In addition, the revenue for the quarter came in significantly higher than the analysts’ predictions of $105.14 million, coming in at $109.14 million instead of the expected amount of $105.14 million. The return on equity for Guardant Health was 99.90%, and the company had a net margin that was negative 135.03% of revenue. In comparison to the same quarter in the previous year, Guardant Health experienced a growth in revenue of 18.5%. The company reported a loss of $0.96 per share during the same period as the previous year. Sell-side analysts anticipate a -6.46 cents per share loss for Guardant Health in the current fiscal year.

Amelia Merrill, the company’s Senior Vice President, sold 4,500 shares of the company’s stock on August 11, according to other recent business-related news. The transaction volume reached a total of $240,210.00 due to the sale of the stock at an average price of $53.38 per share, which resulted in the sale of the stock. The senior vice president is the current owner of 24,708 shares in the company, and the total value of those shares is approximately $1,318,913.04. You can access a document submitted to the Securities and Exchange Commission by clicking on the link provided in the following sentence. This document contains information and an explanation about the transaction that was just completed. In addition, on August 17, an insider of the company named Kumud Kalia sold 2,000 shares of the company’s stock. This piece of information is relevant to the subject matter of this discussion. The stock was sold for a total value of $102,780.00, corresponding to an average price per share of $51.39 and a total volume of transactions equaling that amount. As a result of the successful transaction, the corporate insider now possesses 18,530 shares, which have a value of approximately $952,256.70. On the Securities and Exchange Commission website, one can find a copy of the legal file that disclosed the transaction. This file contains the details of the transaction (SEC).
On top of that, Senior Vice President of Operations Amelia Merrill sold 4,500 shares of the company’s stock on Thursday, August 11. The transaction involved the sale of the shares at an average price of $53.38 per share, which resulted in a total sale volume of $240,210.00. The company’s senior vice president is currently the owner of 24,708 shares of the company, which have a combined value of approximately $1,318,913.04. Disclosures that are related to the sale might be found in this section of the website. Additionally, 5.90% of the company’s total shares are owned by the people who work there.

Just recently, several institutional investors made changes to the distribution of GH stock that their respective organizations held. Compagnie Lombard Odier SCmA spent $40,000 to acquire a new stake in Guardant Health during the second quarter of the fiscal year. This expenditure was carried out. As a result, Captrust Financial Advisors acquired an additional 33.2% of the total number of Guardant Health common stock shares during the second quarter. Following the acquisition of a further 271 shares during the period in question, Captrust Financial Advisors now holds 1,087 shares of the company’s stock. The value of these shares, as of the present moment, is $44,000. Guardant Health made a total investment of $48,000 in the company during the second quarter to purchase a new interest in the company. During the first three months of the year, HM Payson & Co. increased the amount of ownership it has in Guardant Health by 100.0%. HM Payson & Co. now has a total of 1,000 shares of the company’s stock, which are currently valued at $66,000 thanks to additional purchases made over the time that brought the total number of shares owned by the company to 1,000.
And last but not least, during the second quarter, CWM LLC increased its ownership stake in Guardant Health by 73.6%. Since it was last checked, CWM LLC has increased its holdings in the company’s stock by acquiring 735 additional shares, bringing the total value of its holdings to $70,000. Institutional investors and hedge funds own 89.36% of the company’s shares, making them the company’s largest shareholders.

Guardant Health, Inc., a company specializing in precision oncology, provides blood tests, data sets, and analytics in the United States and other countries around the world. Several different tests are based on liquid biopsies and can detect advanced cancer stages. These tests can be found here. Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI are a few examples of these tests. In addition, GuardantINFORM is a research platform that combines a clinical-genomic liquid biopsy dataset of patients with advanced cancer with a virtual environment. This dataset was collected from people who had already been diagnosed with cancer.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue